Tatsuya Tamura

Synthesis and optimization of hyaluronic acid-methotrexate conjugates to maximize benefit in the treatment of osteoarthritis.

Shigeo Sato, Tomoyuki Watanabe, T. Morikawa, 2010, Bioorganic & medicinal chemistry.

Long-Term Treatment with Eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnover and Leads to Prevention of Bone Loss and Bone Fragility in Ovariectomized Rats

Susan Y. Smith, R. Samadfam, S. Takeda, 2014, Calcified Tissue International.

Pharmacodynamic Actions of a Long‐Acting PTH Analog (LA‐PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys

Tomoyuki Watanabe, T. Gardella, J. Potts, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism.

Yoshiaki Watanabe, H. Saito, Y. Isshiki, 2018, Journal of medicinal chemistry.

The Optimal Duration of PTH(1-34) Infusion Is One Hour per Day to Increase Bone Mass in Rats.

Motohiro Kato, M. Nanami, C. Miyaura, 2016, Biological & pharmaceutical bulletin.

Novel hyaluronic acid–methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models

T. Morikawa, R. Saitoh, Haruhiko Sato, 2016, Arthritis Research & Therapy.

Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment.

Shigeo Sato, Tomoyuki Watanabe, T. Morikawa, 2009, Bioorganic & medicinal chemistry.

Optimization of PTH/PTHrP Hybrid Peptides to Derive a Long‐Acting PTH Analog (LA‐PTH)

T. Gardella, J. Potts, Y. Kawabe, 2020, JBMR plus.

Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism

Tomoyuki Watanabe, Y. Kawabe, Haruhiko Sato, 2016, Nature Communications.

Long-Term Treatment with Eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnover and Leads to Prevention of Bone Loss and Bone Fragility in Ovariectomized Rats

Susan Y. Smith, R. Samadfam, S. Takeda, 2014, Calcified Tissue International.

Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist.

Yoshiaki Watanabe, Y. Isshiki, Haruhiko Sato, 2020, Journal of medicinal chemistry.

Pharmacodynamic Actions of a Long‐Acting PTH Analog (LA‐PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys

Tomoyuki Watanabe, T. Gardella, J. Potts, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.